Targeted therapy with 1 of 5 available biologic medications may effectively manage severe asthma.
Siltuximab is currently marketed under the trade name Sylvant and is indicated for the treatment of multicentric Castleman’s disease.
Recommendations by ASAIO on selection and treatment of patients with respiratory and circulatory failure associated with COVID-19 using artificial pulmonary and/or cardiac support.
The Asthma Impairment and Risk Questionnaire was deemed an appropriate measure to identify asthma control status in adults and adolescents that had been validated in a rigorous fashion.
A phase 3 trial evaluating sarilumab, an interleukin-6 antagonist, in patients with COVID-19 requiring mechanical ventilation did not meet its primary and key secondary end points.
Hand sanitizers containing methanol, or wood alcohol, present a danger to individuals as the substance can be toxic when absorbed through the skin or life-threatening if ingested.
Pfizer and BioNTech SE announced positive preliminary results from the phase 1/2 study evaluating the safety, tolerability, and immunogenicity of escalating doses of the vaccine candidate BNT162b1 against COVID-19.
Routine vaccination should not be delayed due to the COVID-19 pandemic, according to interim guidance released by the Centers for Disease Control and Prevention.